Loading...
Please wait, while we are loading the content...
Similar Documents
Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy
| Content Provider | MDPI |
|---|---|
| Author | Colombatto, Piero Palmisano, Elena Ricco, Gabriele Cavallone, Daniela Oliveri, Filippo Coco, Barbara Salvati, Antonio Romagnoli, Veronica Surace, Lidia Vatteroni, Maria Linda Pistello, Mauro Virdis, Agostino Bonino, Ferruccio Brunetto, Maurizia Rossana |
| Copyright Year | 2022 |
| Description | Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) may induce hepatitis B virus (HBV) reactivations in co-infected patients, whose dynamics and outcomes could depend on the phase of HBV infection. We investigated HBsAg and HBV-DNA kinetics in fifteen untreated HBeAg Negative Infection (ENI) (4F-11M, 62.1y) and eight Nucleos(t)ide Analogs (NAs) treated Chronic Hepatitis B (CHB) (3F-6M, 54.8y) with HCV co-infection, receiving DAAs-regimens including Sofosbuvir (13) or not (10). All achieved a sustained virologic response (SVR) and normalized alanine-aminotransferase (ALT). At the direct acting antivirals’ (DAAs) baseline (BL), the HBV-DNA was undetectable (1 Log in five and became detectable in two. Accordingly, mean BL Log-HBV-DNA (0.89) increased at week-4 (1.78; p = 0.100) and at the end of therapy (1.57; p = 0.104). Mean Log-HBsAg decreased at week-4 in ENI (from 0.88 to 0.55; p = 0.020) and CHB (from 2.42 to 2.15; p = 0.015). After DAAs, the HBsAg returned to pre-treatment levels in CHB, but not in ENI (six cleared HBsAg). Female gender and SOF were associated with a greater HBsAg decline. In conclusion, HBV reactivations during DAAs in HCV co-infected ENI caused moderate increases of HBV-DNA without ALT elevations. The concomitant HBsAg decline, although significant, did not modify individual pre-treatment profiles. |
| Starting Page | 1406 |
| e-ISSN | 20770383 |
| DOI | 10.3390/jcm11051406 |
| Journal | Journal of clinical medicine |
| Issue Number | 5 |
| Volume Number | 11 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2022-03-04 |
| Access Restriction | Open |
| Subject Keyword | Journal of clinical medicine Journal of Clinical Medicine Pharmacology and Pharmacy Hepatitis B Virus Hepatitis C Virus Co-infection Direct Acting Antivirals Chronic Hepatitis B Hbeag Negative Infection Reactivation Hepatitis B Surface Antigen Kinetics Interferon Γ-induced Protein 10 |
| Content Type | Text |
| Resource Type | Article |
